Document is current
Any future updates will be listed below
-
Authors
Diop, Khoudia
Benlaïfaoui, Myriam
Hunter, Sébastien
Méndez-Salazar, Eder Orlando
Hakozaki, Taiki
Richard, Corentin
Prifti, Diogjena Katerina
Kourtian, Sylva
Proulx-Rocray, Francis
Naimi, Sabrine
Ponce, Mayra
Messaoudene, Meriem
Cauchois, Florent
Belkaid, Wiam
Bataille, Veronique
Lee, Karla
Mihalcioiu, Catalin
Watson, Ian Robert
Elkrief, Arielle
Routy, Bertrand
-
Funding
Funding for this research was provided by:
Fonds de recherche du Québec (284894)
Canadian Institutes of Health Research
- License Information
-
More Information
Article History
Received: 2 September 2025
Accepted: 1 April 2026
First Online: 4 May 2026
Declarations
:
: Clinical data and samples were approved by the CHUM Ethics Review Board, ethics number: MP-02-2021-9334, through biobank ethical number CE17.035. Participating centers, McGill and King’s College London, patient clinical information and samples were respectively collected under the protocol number 2019–4778 and from the clinical trial PRIMM (NCT03643289).
: Not applicable.
: BR declares research funding from Davolterra, Kanvas Bioscience, consulting fees from Merck, AstraZeneca, Vendata and BMS, and is a co-founder of Curebiota. AE declares grant support from Kanvas Bioscience, GMT Science, Astrazeneca, Merck, and BMS. AE declares honoraria from Astrazeneca, Merck, BMS, and EMD Soreno. AE is inventor on a patent 4872-8531-1934.1 regarding the microbiome and immunotherapy response.
